The ADAPT-PD trial validated aDBS's safety and efficacy, showing advantages over traditional continuous DBS methods. The ...
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...
The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback